Сравнительная оценка протезов, используемых для транскатетерной имплантации аортального клапана

Abstract

As a result of the research results are as follows. Paravalvular regurgitation 0-1 level on the first day after surgery was more frequent in the prosthesis ES (56% more than in the CV, p<0,05), I—II — in the CV (33.3% more, p <0,05); 3 months: 0-1 level on the first day after surgery was more frequent in the ES (at 71.42% more than in the CV, p<0,05); 12 months: 0-1 level — for ES (33.3 more than your CV, p<0,05). Reduction of PG in the first day after the operation was significantly more pronounced in the ES (15 mmHg, compared with the CV, p<0,05), and 9 and 12 months — CV (2.05 and 3,9 mmHg, respectively, p< 0.05) mg on the first day after surgery — for ES (at 6,72 mmHg, p<0,05), and 12 months — CV (at 2,3 mmHg, p<0,05). Reduced EDV and ESV in first day after surgery and for 3 months significantly greater in the ES (11.2 and 8.95 ml, p<0,05), 6,9,12 months to align the results.

Цель исследования. Проанализировать гемодинамические особенности протезов аортального клапана MEDTRONIC Core Valve ReValving system (CV) и EDWARDS Sapien valve (ES) в ближайшем и средне­отдалённом послеоперационном периоде.